**Name of Journal:** *World Journal of Gastrointestinal Oncology*

**Manuscript NO:** 60709

**Manuscript Type:** META-ANALYSIS

**Efficacy and safety of intraoperative radiotherapy in rectal cancer: A systematic review and meta-analysis**

Liu B *et al*. Meta-analysis of intraoperative radiotherapy in rectal cancer

Bin Liu, Long Ge, Jing Wang, Ya-Qiong Chen, Shi-Xun Ma, Pei-Lan Ma, Yun-Qiang Zhang, Ke-Hu Yang, Hui Cai

**Bin Liu, Ya-Qiong Chen, Shi-Xun Ma, Pei-Lan Ma, Yun-Qiang Zhang,** Gansu Provincial Hospital, General Surgery Clinical Medical Center, Lanzhou 730000, Gansu Province, China

**Long Ge,** Evidence Based Social Science Research Center, School of Public Health, Lanzhou University, Lanzhou 730000, Gansu Province, China

**Jing Wang,** Gansu University of Chinese Medicine, Gansu University of Chinese Medicine, Lanzhou 730000, Gansu Province, China

**Ke-Hu Yang,** Evidence Based Medicine Center, School of Basic Medical Sciences, Lanzhou University, Lanzhou 730000, Gansu Province, China

**Hui Cai,** General Surgery Clinical Medical Center, Gansu Provincial Hospital, Lanzhou 730000, Gansu Province, China

**Author contributions:** Liu B, Ge L, Yang KH, and Cai H designed the research; Liu B, Wang J, Chen YQ, Ma SX, and Ma PL conducted the literature search; Liu B and Ge L collected and retrieved the data; Liu B, Zhang YQ, and Wang YF analyzed the data; Liu B wrote and revised the manuscript; All authors approved the final version.

**Supported by** Natural Science Foundation of Gansu Province, China, No. 18JR3RA052; Gansu Province Da Vinci robot high end diagnosis and treatment personnel training project; National Key Research and Development Program Task Book, No. 2018YFC1311506; Lanzhou Talent Innovation and Entrepreneurship Project Task Contract, No. 2016-RC-56; 2019 Graduate Innovation Fund Project, No. 2020CX50.

**Corresponding author: Hui Cai, MD, PhD, Chief Doctor, Director, Professor, Surgical Oncologist,** General Surgery Clinical Medical Center, Gansu Provincial Hospital, Lanzhou 730000, Gansu Province, China. caialonteam@163.com

**Received:** November 10, 2020

**Revised:** December 6, 2020

**Accepted:** December 16, 2020

**Published online:**

**Abstract**

BACKGROUND

In recent years, intraoperative radiotherapy (IORT) has been increasingly used for the treatment of rectal cancer. However, the efficacy and safety of IORT for the treatment of rectal cancer are still controversial.

AIM

To evaluate the value of IORT for patients with rectal cancer.

METHODS

We searched PubMed, Embase, Cochrane Library, Web of Science databases, and conference abstracts and included randomized controlled trials and observational studies on IORT *vs* non-IORT for rectal cancer. Dichotomous variables were evaluated by odds ratio (OR) and 95% confidence interval (CI), hazard ratio (HR) and 95%CI was used as a summary statistic of survival outcomes. Statistical analyses were performed using Stata V.15.0 and Review Manager 5.3 software.

RESULTS

In this study, 3 randomized controlled studies and 12 observational studies were included with a total of 1460 patients, who are mainly residents of Europe, the United States, and Asia. Our results did not show significant differences in 5-year overall survival (HR = 0.80, 95%CI = 0.60-1.06; *P* = 0.126); 5-year disease-free survival (HR = 0.94, 95%CI = 0.73-1.22; *P* = 0.650); abscess (OR = 1.10, 95%CI = 0.67-1.80; *P* = 0.713), fistulae (OR = 0.79, 95%CI = 0.33-1.89; *P* = 0.600); wound complication (OR = 1.21, 95%CI = 0.62-2.36; *P* = 0.575); anastomotic leakage (OR = 1.09, 95%CI = 0.59-2.02; *P* = 0.775); and neurogenic bladder dysfunction (OR = 0.69, 95%CI = 0.31-1.55; *P* = 0.369). However, the meta-analysis of 5-year local control was significantly different (OR = 3.07, 95%CI = 1.66-5.66; *P* = 0.000).

CONCLUSION

The advantage of IORT is mainly reflected in 5-year local control, but it is not statistically significant for 5-year overall survival, 5-year disease-free survival, and complications.

**Key Words:** Intraoperative radiotherapy; Rectal cancer; Systematic review; External beam radiation therapy; Randomized controlled trials; Meta-analysis

Liu B, Ge L, Wang J, Chen YQ, Ma SX, Ma PL, Zhang YQ, Yang KH, Cai H. Efficacy and safety of intraoperative radiotherapy in rectal cancer: A systematic review and meta-analysis. *World J Gastrointest Oncol* 2020; In press

**Core Tip:** Rectal cancer is one of the malignant tumors with a high fatality rate in the world. Intraoperative radiotherapy (IORT) allows for direct administration of high-dose radiation and the area that is at the greatest risk after resection. Although research reports on IORT for rectal cancer have been published, there is still a lack of reliable evidence regarding treatment efficacy and safety. Therefore, we conducted a systematic review and meta-analysis to evaluate the efficacy and safety of IORT for the treatment of rectal cancer.

**INTRODUCTION**

Rectal cancer is a common malignant tumor of the digestive tract[1]. Because of its characteristics of being difficult to locate, high mortality, and poor prognosis, it is a killer, thereby threatening human health[2]. Surgical resection is one of the main clinical treatment methods, and tumor tissue can be removed as much as possible to achieve good clinical treatment results[3]. Currently, laparoscopic surgery is commonly used in the clinical treatment of rectal cancer[4]. For advanced or recurrent rectal cancer, the combination of surgery and radiotherapy can prolong the survival rate of patients, but external beam radiation therapy (EBRT) alone has a poor response to treatment and a high recurrence rate[5,6].

Intraoperative radiotherapy (IORT) involves the precise delivery of large doses of ionizing radiation to a tumor or tumor bed during surgery[7,8]. Direct visualization of the tumor bed and the ability to separate healthy tissue from the tumor bed maximize the radiation dose to the tumor, while minimizing the dose to healthy tissue, thereby leading to an increased treatment rate for IORT[9,10]. Although IORT was introduced in the 1960s[5], its popularity increased with the introduction of self-shielding mobile linear accelerators and low-voltage IORT devices[11]. In May 2019, the American Society of Brachytherapy reached a consensus on IORT: IORT can be considered at the time of surgical resection of locally advanced or recurrent colorectal cancer in cases with concern for a positive margin, particularly when pelvic EBRT has already been delivered[12]. The National Comprehensive Cancer Network guidelines for the treatment of rectal cancer (Version 4.2020) described the following: IORT, if available, may be considered for very close or positive margins after resection, as an additional boost, especially for patients with T4 or recurrent cancers[13]. At present, the number of studies that focus on IORT is increasing and includes breast cancer, colorectal cancer, pancreatic cancer, gastric cancer, head and neck cancer, glioma, and gynecological tumors[14-16].

In the past 10 years, cases of rectal cancer patients receiving IORT have gradually increased[17]. In previous studies[18], it was demonstrated that adding IORT to traditional treatment of rectal cancer not only reduces the local recurrence rate of advanced rectal cancer but also influences the local control (LC) rate of locally recurrent rectal cancer. However, a recent randomized controlled trial (RCT) showed that IORT cannot be recommended as a standard therapy to compensate less radical resection for advanced lower rectal cancer[19]. Although several research reports on IORT for the treatment of rectal cancer have been published, due to the small sample size, there is still a lack of reliable evidence regarding the efficacy and safety of IORT.

Therefore, to draw more reliable conclusions, we conducted a systematic review and meta-analysis to evaluate the effectiveness and safety of IORT *vs* non-IORT in the treatment of rectal cancer.

**MATERIALS AND METHODS**

This systematic review and meta-analysis are reported in accordance with the Preferred Reporting Items for Systematic Review and Meta-Analysis statement[20].

***Search strategy***

Up to November 2020, PubMed, Embase, Cochrane Library, Web of Science, letters to the editor and abstracts of conferences were searched to compare the efficacy and safety of IORT and non-IORT for the treatment of rectal cancer. The following medical subject heading terms and keywords were used: “intraoperative radiotherapy,” “IORT,” “intra-operative radiation therapy,” “intraoperative radiation therapy,” “rectal neoplasms,” and “rectal cancer.” The search strategy for PubMed is revealed in the supplementary material (Item 1).

***Selection criteria***

Studies were included if the RCT and observational study published compared IORT and non-IORT treatment for rectal cancer, and at least 20 patients were included in the study. Studies were excluded if the study was a review, expert opinion, or meta-analysis, lack of original data, no control group, duplicate studies, and animal studies.

Titles and abstracts of retrieved studies were screened by two independent reviewers, and any conflicts were resolved by discussion. Any potentially eligible study was retrieved for further reviewer.

***Data extraction and quality assessment***

Two reviewers (BL and LG) independently assessed the eligibility of each trail and extracted the data (first author name, publication date, country/region, study type, number of patients per group, age, tumor site, stage, pre-operative radiotherapy; chemotherapy; post-operative radiotherapy and IORT dose from each study. The main results were 5-year overall survival (OS), 5-year disease-free survival (DFS), 5-year LC, and complications (abscess, fistulae, wound complications, anastomotic leakage, and neurogenic bladder dysfunction).

The Cochrane risk of bias tool[21] was used to evaluate the quality of RCTs including selection bias, performance bias, detection bias, attrition bias, reporting bias, and other bias through high-risk, low-risk, and unknown risk. The quality of the study was assessed by the Newcastle-Ottawa Scale[22] for observational studies. We analyzed the representativeness of the exposed observational, selection of the non-exposed observational, ascertainment of exposure, demonstration that outcome of interest was not present at the start of the study, comparability of cohorts based on the design and analysis, assessment of outcome, whether follow-up time was long enough for outcomes to occur, and the adequacy of follow-up of the cohorts. A score of 0-9 was assigned to each study. In general, studies were considered of high quality if a score of 6 was reached. Disagreements were resolved by discussion and consultation with the senior investigator.

***Statistical analysis***

Dichotomous variables were evaluated by odds ratio (OR) and 95% confidence interval (CI), including LC and complication results. In addition, hazard ratio (HR) was used as a summary statistic of survival outcomes (5-year OS and 5-year DFS). Heterogeneity was evaluated using the Higgins *I*2 value, and values < 25, 25 to 50, and > 50 were defined as corresponding to low, moderate, and high heterogeneity, respectively. The OR and HR values are reported with the 95%CIs. *P* < 0.05 was considered statistically significant. All statistical analyses were performed with Review Manager 5.3 software (Cochrane Collaboration’s Information Management System) and Stata version 15.0 software (STATA, College Station, TX, United States).

Subgroup analysis was performed on the basis of study type, and sensitivity analysis was performed on the outcome indicators of more than 10 studies to explore their potential sources and assess the robustness of these results. The Begg’s test and Egger’s test were used to test publication bias.

**RESULTS**

***Search results***

Initially, 645 studies were included in the study through electronic retrieval. A total of 169 duplicate studies were removed and 448 articles were excluded after reading the title and abstract; thus, a total of 28 studies were obtained. After reading the full text, another 15 studies were excluded. Finally, 15[19,23-36] studies were included, involving 1460 patients (687 in the IORT group, 773 in the non-IORT group). The studies included 3 RCTs[19,30,32] and 12 observational studies[23-29,31,33-36] comparing IORT with non-IORT for rectal cancer. Tables 1 and 2 summarize the baseline characteristics of the included studies. Basic characteristics of the included studies were as follows. (1) There was a large sample size gap between the studies, with the largest being 163 cases[34] and the smallest being 43 cases[27]. (2) The publication year of the literature varied greatly, and the time span ranged from 1991 to 2020. (3) The literature was mainly obtained from European, American, and Asian countries. (4) The literature mostly consisted of observational studies and a few RCTs.

The quality of RCTs showed that attrition bias was at high risk and the quality of all observational studies showed that two studies received nine stars, four received eight stars, and four received seven stars (Table 1). Figure 1 presents the screening flow chart of the included studies. Figure 2 shows the quality assessment of the three RCTs, which indicates that the overall quality of the three RCTs was sufficient.

***Meta-analysis results***

The results of the meta-analysis were arbitrated by the study type subgroup (RCTs and observational studies) (Table 3).

***Five-year OS and five-year DFS***

A total of 9[19,25,26,28,30-32,35,36]of the 15 studies included the 5-year OS results reported in their results (Figure 3A). We did not observe statistically significant differences in the meta-analysis (HR = 0.80, 95%CI = 0.60-1.06; *P* = 0.189). The meta-analysis of RCTs (HR = 0.68, 95%CI = 0.29-1.63; *P* = 0.390) and observational studies (HR = 0.81, 95%CI = 0.60-1.11; *P* = 0.189) also showed similar results. Furthermore, the results showed no heterogeneity in the subgroup of observational studies (*c2*= 2.21, *I2*= 0.0%; *P* = 0.819).

In 6[23,28,30,32,35,36]of the 13 studies, a 5-year DFS period was reported (Figure 3B). No significant differences were observed in the data: totality (HR = 0.94, 95%CI = 0.73-1.22; *P* = 0.650). The meta-analysis of RCTs (HR = 1.61, 95%CI = 0.74-3.53; *P* = 0.231) and observational studies (HR = 0.89, 95%CI = 0.68-1.16; *P* = 0.378) showed similar results. The results showed no heterogeneity in the subgroup of observational studies (*c2* = 1.72, *I2* = 0.0%; *P* = 0.633).

***Five-year local control***

In 14[19,23-33,35,36]cases, the meta-analysis of 5-year LC revealed statistically significant differences (OR = 3.07, 95%CI = 1.66-5.66; *P* = 0.000) (Figure 4). However, the meta-analysis of RCTs (OR = 1.37, 95%CI = 0.35-5.35; *P* = 0.655) and observational studies (OR = 3.45, 95%CI = 1.54-7.73; *P* = 0.000) showed different results. High heterogeneity was found in the subgroup of observational studies (*c2*= 41.31, *I2*= 73.4%; *P* = 0.000).

***Abscess***

In 6[19,24,26,30,33,34] of the 13 studies, abscess results reported were included in the study (Figure 5). No statistical significance was observed (OR = 1.10, 95%CI = 0.67-1.80; *P* = 0.833). The meta-analysis of RCTs (OR = 1.83, 95%CI = 0.65-5.11; *P* = 0.252) and observational studies (OR = 0.94, 95%CI = 0.53-1.66; *P* = 0.833) also showed similar results. The results showed no heterogeneity in the subgroup of observational studies (*c2* = 1.99, *I2* = 0.0%; *P* = 0.575).

***Fistulae***

In 3[24,32,34]of the 13 studies, the fistulae results were included in the study (Figure 6). The results were not statistically significant (OR = 0.79, 95%CI = 0.33-1.89; *P* = 0.600). The meta-analysis of RCTs (OR = 0.75, 95%CI = 0.30-1.88; *P* = 0.542) and observational studies (OR = 1.22, 95%CI = 0.08-18.77; *P* = 0.888) showed similar results. High heterogeneity was found in the subgroup of observational studies (*c2*= 2.02, *I2*= 50.4%; *P* = 0.156).

***Wound complications***

In 8[24-26,28,32-35]of the 13 cases, wound complications results were included in the study (Figure 7) and were not statistically significant (OR = 1.02, 95%CI = 0.52-2.02; *P* = 0.948). The meta-analysis of RCTs (OR = 0.75, 95%CI = 0.30-1.88; *P* = 0.542) and observational studies (OR = 1.06, 95%CI = 0.47-2.37; *P* = 0.893) also showed similar results. High heterogeneity was found in the subgroup of observational studies (*c2*= 16.09, *I2*= 62.7%; *P* = 0.013).

***Anastomotic leakage***

In 7[19,26,28,30,32-34]of the 13 cases, the anastomotic leakage results were not statistically significant (OR = 1.09, 95%CI = 0.59-2.02; *P* = 0.775) (Figure 8). RCTs (OR = 2.18, 95%CI = 0.89-5.33; *P* = 0.087) and observational studies (OR = 0.66, 95%CI = 0.31-1.41; *P* = 0.283) The results showed no heterogeneity in the subgroup of observational studies (*c2* = 2.46, *I2* = 0.0%; *P* = 0.482).

***Neurogenic bladder dysfunction***

In 3[25,28,34]of the 13 cases, the neurogenic bladder dysfunction results were included in the study (Figure 9). No statistically significant differences were observed (OR = 0.69, 95%CI = 0.31-1.55; *P* = 0.369). The results showed no heterogeneity in the subgroup of observational studies (*c2* = 0.25, *I2* = 0.0%; *P* = 0.874).

***Publication bias and sensitivity analysis***

Our data showed that Begg’s tests (*P* = 0.855) and Egger’s tests (*P* = 0.483) did not have publication bias (Figure 10). Sensitivity analysis on the primary outcomes was performed with high and moderate heterogeneity (5-year LC, fistulae, and wound complications) to explore their potential source and assess the robustness of these outcomes. After ignoring each included study in turn for each outcome, the results of 5-year LC, fistulae, and wound complications were stable after testing.

**DISCUSSION**

For the treatment of rectal cancer, total mesorectal excision is a treatment method that clearly improves the condition; however, recurrence is a major challenge for the prognosis of patients[37]. Multidisciplinary treatment methods including surgery, chemotherapy and radiotherapy significantly improve the prognosis of patients[38]. The total dose of radiotherapy may be an important determinant of LC of advanced and recurrent tumors; however, treatment with EBRT alone has not achieved sufficient results[39]. Therefore, IORT allows for the direct administration of high-dose radiation and the area that is at the greatest risk after resection[40]. Although research reports on IORT for rectal cancer have been published, the sample sizes were small, and therefore, there is still a lack of reliable evidence regarding treatment efficacy and safety. The systematic review and meta-analysis of this study show that IORT is associated with improved LC after resection.

When subgroup analysis was conducted by study type (RCTs or observational studies), the 5-year survival rate, fistulae, and wound complications showed moderate heterogeneity, which were likely to be different from the original research design, racial various, and inconsistent measurement methods[41]. Concerning the 5-year survival rate, whether or not to undergo preoperative radiotherapy, postoperative radiotherapy, and chemotherapy regimen may be influencing factors in all studies included. In addition, differences in the dose of IORT will likely lead to a shift in survival rates in each study[42]. The difference in complication results may be due to the longer IORT time compared with simple surgery and more blood loss[43]. The studies included primary rectal cancer and recurrent rectal cancer. Due to the destruction of the anatomical plane in cases with recurrent rectal cancer[44] as well as the limitation of the pelvic area, achieving an R0 resection is more complicated. In addition, compared with primary rectal cancer, a more systematic radiotherapy and chemotherapy regimen was received before surgery, thereby leading to differences in both outcomes and bias[45].

The benefit of IORT after R0 resection is a potential confounding factor between studies[46]. Many reports have confirmed that the 5-year DFS rate of the IORT group and non-IORT group after R0 resection is equivalent[31,36]. In addition, in a recent RCT[19], IORT and non-IORT treatment were compared and the 5-year overall survival rates were 71.5% and 81.8%, respectively, and support the view that IORT may not be beneficial after complete tumor resection. When compared with patients who did not receive adjuvant therapy (preoperative radiotherapy, postoperative radiotherapy, chemotherapy), patients who received adjuvant therapy clearly showed beneficial effects of the treatment[28,32,36], which indicates the importance of adjuvant therapy for IORT.

In this study, we present the first pooled analysis of the impact of IORT on long-term oncology outcomes after rectal cancer resection. In a previous study, the safety and effectiveness of IORT in the treatment of colorectal cancer was systematically evaluated in 2011[47], and in one study, the benefits of IORT treatment for colorectal cancer were reported in 2013[48]. However, due to the differences in anatomical location and biological function between colon cancer and rectal cancer, we analyzed rectal cancer separately. By contrast to previous studies, our research incorporated more original studies and detailed subgroup analysis and sensitivity analysis were performed. Despite the inherent limitations of meta-analysis using observational studies, our findings suggested that the use of IORT during rectal cancer surgery may improve LC and has a more moderate impact on disease prognosis and survival. The application of IORT in the treatment of various types of tumors has significant benefits. Indeed, early breast cancer patients who received IORT during breast-conserving surgery had a better survival period[49], and in patients with brain metastases, using IORT can deliver auxiliary radiation to the resection cavity with a high LC rate and low incidence of radiation necrosis[50].

This research also had limitations. At first, the randomization in the original research was limited. There were few controlled experiments and the sample size was irregular. Second, although most patients were treated in large tertiary cancer centers, the inclusion criteria for patients were different[51]. Moreover, during treatment, the assessment methods of the outcome index was related to the proficiency of the surgeon. In addition, there were differences in the surgical procedures in this research, which may be a confounding factor for the results. Finally, our research is a secondary study and differences in the original data cannot be controlled for, including experimental design, inclusion criteria, and the original study included, which may affect the reliability of the results.

**CONCLUSION**

Our findings demonstrate that in patients with rectal cancer, adding IORT to traditional multimodal treatment strategies can improve LC but does not significantly improve the survival rate and complications of patients. In the future, well-designed prospective RCTs are warranted to better define the treatment effects using IORT.

**ARTICLE HIGHLIGHTS**

***Research background***

The prognosis of patients with rectal cancer is poor and the mortality rate is high. The effectiveness and safety of intraoperative radiotherapy (IORT) for rectal cancer still controversial.

***Research motivation***

Previous studies have demonstrated that adding IORT to traditional treatment of rectal cancer not only reduces the local recurrence rate of advanced rectal cancer but also influences the local control rate of locally recurrent rectal cancer. However, a recent randomized controlled trial (RCT) showed that IORT cannot be recommended as a standard therapy to compensate less radical resection for advanced lower rectal cancer. It is necessary to perform a meta-analysis to systematically and comprehensively investigate the effectiveness and safety of IORT in the treatment of rectal cancer.

***Research objectives***

A systematic review and meta-analysis to evaluate the value of IORT for patients with rectal cancer.

***Research methods***

We searched PubMed, Embase, Cochrane Library, Web of Science databases and conference abstracts and included RCTs and observational studies on IORT *vs* non-IORT for rectal cancer. Dichotomous variables were evaluated by odds ratio (OR) and 95% confidence interval (CI), hazard ratio (HR) and 95%CI was used as a summary statistic of survival outcomes. Statistical analyses were performed using Stata V.15.0 and Review Manager 5.3 software.

***Research results***

In this study, 3 RCTs and 12 observational studies were included with a total of 1460 patients, who were mainly residents of Europe, the United States, and Asia. Our results did not show significant differences in 5-year overall survival (HR = 0.80, 95%CI = 0.60-1.06; *P* = 0.126), 5-year disease-free survival (HR = 0.94, 95%CI = 0.73-1.22; *P* = 0.650); abscess: (OR = 1.10, 95%CI = 0.67-1.80; *P* = 0.713); fistulae (OR = 0.79, 95%CI = 0.33-1.89; *P* = 0.600); wound complication (OR = 1.21, 95%CI = 0.62-2.36; *P* = 0.575); anastomotic leakage (OR = 1.09, 95%CI = 0.59-2.02; *P* = 0.775); and neurogenic bladder dysfunction (OR = 0.69, 95%CI = 0.31-1.55; *P* = 0.369). However, the meta-analysis of 5-year local control was significantly different (OR = 3.07, 95%CI = 1.66-5.66; *P* = 0.000).

***Research conclusions***

The advantage of IORT is mainly reflected in 5-year local control but it is not statistically significant for 5-year overall survival, 5-year disease-free survival, and complications.

***Research perspectives***

Several limitations in this analysis should be carefully addressed. First, the randomization in the original research was limited. There were few controlled experiments and the sample size was irregular. Second, although most patients were treated in large tertiary cancer centers, the inclusion criteria for patients were different[51]. Moreover, during treatment, the assessment methods of the outcome index was related to the proficiency of the surgeon. In addition, there were differences in the surgical procedures in this research, which may be a confounding factor for the results. Finally, our research is a secondary study and differences in the original data cannot be controlled for, including experimental design, inclusion criteria, and the original study included, which may affect the reliability of the results.

**ACKNOWLEDGEMENTS**

The authors thank Key Laboratory of Molecular Diagnostics and Precision Medicine for Surgical Oncology in Gansu Province and the DaVinci Surgery System Database (DSSD, www.davincisurgerydatabase.com) and for their help and support in the methodology and meta-analysis process.

**REFERENCES**

1 **Mishra N**. Locally Recurrent Rectal Cancer. *Dis Colon Rectum* 2018; **61**: 651-654 [PMID: 29722723 DOI: 10.1097/DCR.0000000000001111]

2 **Potemin S**, Kübler J, Uvarov I, Wenz F, Giordano F. Intraoperative radiotherapy as an immediate adjuvant treatment of rectal cancer due to limited access to external-beam radiotherapy. *Radiat Oncol* 2020; **15**: 11 [PMID: 31924250 DOI: 10.1186/s13014-020-1458-y]

3 **Chen EY**, Kardosh A, Nabavizadeh N, Lopez CD. Evolving Treatment Options and Future Directions for Locally Advanced Rectal Cancer. *Clin Colorectal Cancer* 2019; **18**: 231-237 [PMID: 31377214 DOI: 10.1016/j.clcc.2019.06.005]

4 **Wilkinson N**. Management of Rectal Cancer. *Surg Clin North Am* 2020; **100**: 615-628 [PMID: 32402304 DOI: 10.1016/j.suc.2020.02.014]

5 **Feeney G**, Sehgal R, Sheehan M, Hogan A, Regan M, Joyce M, Kerin M. Neoadjuvant radiotherapy for rectal cancer management. *World J Gastroenterol* 2019; **25**: 4850-4869 [PMID: 31543678 DOI: 10.3748/wjg.v25.i33.4850]

6 **Kane C**, Glynne-Jones R. Should we favour the use of 5 × 5 preoperative radiation in rectal cancer. *Cancer Treat Rev* 2019; **81**: 101908 [PMID: 31683174 DOI: 10.1016/j.ctrv.2019.101908]

7 **Harris EER**, Small W Jr. Intraoperative Radiotherapy for Breast Cancer. *Front Oncol* 2017; **7**: 317 [PMID: 29312887 DOI: 10.3389/fonc.2017.00317]

8 **Backes FJ**, Martin DD. Intraoperative radiation therapy (IORT) for gynecologic malignancies. *Gynecol Oncol* 2015; **138**: 449-456 [PMID: 26033307 DOI: 10.1016/j.ygyno.2015.05.030]

9 **Van De Voorde L**, Delrue L, van Eijkeren M, De Meerleer G. Radiotherapy and surgery-an indispensable duo in the treatment of retroperitoneal sarcoma. *Cancer* 2011; **117**: 4355-4364 [PMID: 21446048 DOI: 10.1002/cncr.26071]

10 **Lunsford LD**, Niranjan A, Kano H, Kondziolka D. The technical evolution of gamma knife radiosurgery for arteriovenous malformations. *Prog Neurol Surg* 2013; **27**: 22-34 [PMID: 23258506 DOI: 10.1159/000341625]

11 **Sedlmayer F**, Reitsamer R, Wenz F, Sperk E, Fussl C, Kaiser J, Ziegler I, Zehentmayr F, Deutschmann H, Kopp P, Fastner G. Intraoperative radiotherapy (IORT) as boost in breast cancer. *Radiat Oncol* 2017; **12**: 23 [PMID: 28103903 DOI: 10.1186/s13014-016-0749-9]

12 **Tom MC**, Joshi N, Vicini F, Chang AJ, Hong TS, Showalter TN, Chao ST, Wolden S, Wu AJ, Martin D, Husain Z, Badiyan SN, Kolar M, Sherertz T, Mourtada F, Cohen GN, Shah C. The American Brachytherapy Society consensus statement on intraoperative radiation therapy. *Brachytherapy* 2019; **18**: 242-257 [PMID: 31084904 DOI: 10.1016/j.brachy.2019.01.015]

13 **Benson AB**, Venook AP, Al-Hawary MM, Cederquist L, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D, Engstrom PF, Grem JL, Grothey A, Hochster HS, Hoffe S, Hunt S, Kamel A, Kirilcuk N, Krishnamurthi S, Messersmith WA, Meyerhardt J, Mulcahy MF, Murphy JD, Nurkin S, Saltz L, Sharma S, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Wuthrick E, Gregory KM, Gurski L, Freedman-Cass DA. Rectal Cancer, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw* 2018; **16**: 874-901 [PMID: 30006429 DOI: 10.6004/jnccn.2018.0061]

14 **Wallace HJ 3rd**, Goodwin JH. Intraoperative radiation therapy. *Crit Rev Eukaryot Gene Expr* 2012; **22**: 269-279 [PMID: 23272797 DOI: 10.1615/critreveukargeneexpr.v22.i4.10]

15 **Kyrgias G**, Hajiioannou J, Tolia M, Kouloulias V, Lachanas V, Skoulakis C, Skarlatos I, Rapidis A, Bizakis I. Intraoperative radiation therapy (IORT) in head and neck cancer: A systematic review. *Medicine (Baltimore)* 2016; **95**: e5035 [PMID: 27977569 DOI: 10.1097/md.0000000000005035]

16 **Ash RB**, Williams VL, Wagman LD, Forouzannia A. Intraoperative radiotherapy for breast cancer: its perceived simplicity. *Oncology (Williston Park)* 2013; **27**: 107-113 [PMID: 23530401]

17 **Holmes DR**, Zimmerman R. Intraoperative radiotherapy: Patient selection, management, and follow-up. *J Surg Oncol* 2017; **116**: 824-830 [PMID: 28715150 DOI: 10.1002/jso.24734]

18 **Haddock MG**. Intraoperative radiation therapy for colon and rectal cancers: a clinical review. *Radiat Oncol* 2017; **12**: 11 [PMID: 28077144 DOI: 10.1186/s13014-016-0752-1]

19 **Masaki T**, Matsuoka H, Kishiki T, Kojima K, Aso N, Beniya A, Tonari A, Takayama M, Abe N, Sunami E. Intraoperative radiotherapy for resectable advanced lower rectal cancer-final results of a randomized controlled trial (UMIN000021353). *Langenbecks Arch Surg* 2020; **405**: 247-254 [PMID: 32347365 DOI: 10.1007/s00423-020-01875-2]

20 **Pieper D**, Buechter RB, Li L, Prediger B, Eikermann M. Systematic review found AMSTAR, but not R(evised)-AMSTAR, to have good measurement properties. *J Clin Epidemiol* 2015; **68**: 574-583 [PMID: 25638457 DOI: 10.1016/j.jclinepi.2014.12.009]

21 **Liberati A**, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. *BMJ* 2009; **339**: b2700 [PMID: 19622552 DOI: 10.1136/bmj.b2700]

22 **Stang A**. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. *Eur J Epidemiol* 2010; **25**: 603-605 [PMID: 20652370 DOI: 10.1007/s10654-010-9491-z]

23 **Willett CG**, Shellito PC, Rodkey GV, Wood WC. Preoperative irradiation for tethered rectal carcinoma. *Radiother Oncol* 1991; **21**: 141-142 [PMID: 1866465 DOI: 10.1016/0167-8140(91)90087-w]

24 **Suzuki K**, Gunderson LL, Devine RM, Weaver AL, Dozois RR, Ilstrup DM, Martenson JA, O'Connell MJ. Intraoperative irradiation after palliative surgery for locally recurrent rectal cancer. *Cancer* 1995; **75**: 939-952 [PMID: 7531113 DOI: 10.1002/1097-0142(19950215)75:4<939::aid-cncr2820750408>3.0.co;2-e]

25 **Huber FT**, Stepan R, Zimmermann F, Fink U, Molls M, Siewert JR. Locally advanced rectal cancer: resection and intraoperative radiotherapy using the flab method combined with preoperative or postoperative radiochemotherapy. *Dis Colon Rectum* 1996; **39**: 774-779 [PMID: 8674370 DOI: 10.1007/bf02054443]

26 **Wiig JN**, Tveit KM, Poulsen JP, Olsen DR, Giercksky KE. Preoperative irradiation and surgery for recurrent rectal cancer. Will intraoperative radiotherapy (IORT) be of additional benefit? A prospective study. *Radiother Oncol* 2002; **62**: 207-213 [PMID: 11937248 DOI: 10.1016/s0167-8140(01)00486-8]

27 **Ratto C**, Valentini V, Morganti AG, Barbaro B, Coco C, Sofo L, Balducci M, Gentile PC, Pacelli F, Doglietto GB, Picciocchi A, Cellini N. Combined-modality therapy in locally advanced primary rectal cancer. *Dis Colon Rectum* 2003; **46**: 59-67 [PMID: 12544523 DOI: 10.1007/s10350-004-6497-1]

28 **Sadahiro S**, Suzuki T, Ishikawa K, Fukasawa M, Saguchi T, Yasuda S, Makuuchi H, Murayama C, Ohizumi Y. Preoperative radio/chemo-radiotherapy in combination with intraoperative radiotherapy for T3-4Nx rectal cancer. *Eur J Surg Oncol* 2004; **30**: 750-758 [PMID: 15296989 DOI: 10.1016/j.ejso.2004.04.012]

29 **Ferenschild FT**, Vermaas M, Nuyttens JJ, Graveland WJ, Marinelli AW, van der Sijp JR, Wiggers T, Verhoef C, Eggermont AM, de Wilt JH. Value of intraoperative radiotherapy in locally advanced rectal cancer. *Dis Colon Rectum* 2006; **49**: 1257-1265 [PMID: 16912909 DOI: 10.1007/s10350-006-0651-x]

30 **Masaki T**, Takayama M, Matsuoka H, Abe N, Ueki H, Sugiyama M, Tonari A, Kusuda J, Mizumoto S, Atomi Y. Intraoperative radiotherapy for oncological and function-preserving surgery in patients with advanced lower rectal cancer. *Langenbecks Arch Surg* 2008; **393**: 173-180 [PMID: 18172677 DOI: 10.1007/s00423-007-0260-8]

31 **Valentini V**, Coco C, Rizzo G, Manno A, Crucitti A, Mattana C, Ratto C, Verbo A, Vecchio FM, Barbaro B, Gambacorta MA, Montoro C, Barba MC, Sofo L, Papa V, Menghi R, D'Ugo DM, Doglietto G. Outcomes of clinical T4M0 extra-peritoneal rectal cancer treated with preoperative radiochemotherapy and surgery: a prospective evaluation of a single institutional experience. *Surgery* 2009; **145**: 486-494 [PMID: 19375606 DOI: 10.1016/j.surg.2009.01.007]

32 **Dubois JB**, Bussieres E, Richaud P, Rouanet P, Becouarn Y, Mathoulin-Pélissier S, Saint-Aubert B, Ychou M. Intra-operative radiotherapy of rectal cancer: results of the French multi-institutional randomized study. *Radiother Oncol* 2011; **98**: 298-303 [PMID: 21339010 DOI: 10.1016/j.radonc.2011.01.017]

33 **Alberda WJ**, Verhoef C, Nuyttens JJ, van Meerten E, Rothbarth J, de Wilt JH, Burger JW. Intraoperative radiation therapy reduces local recurrence rates in patients with microscopically involved circumferential resection margins after resection of locally advanced rectal cancer. *Int J Radiat Oncol Biol Phys* 2014; **88**: 1032-1040 [PMID: 24661656 DOI: 10.1016/j.ijrobp.2014.01.014]

34 **Klink CD**, Binnebösel M, Holy R, Neumann UP, Junge K. Influence of intraoperative radiotherapy (IORT) on perioperative outcome after surgical resection of rectal cancer. *World J Surg* 2014; **38**: 992-996 [PMID: 24178183 DOI: 10.1007/s00268-013-2313-1]

35 **Zhang Q**, Tey J, Yang Z, Li P, Peng L, Jiang R, Xiong F, Fu S, Lu JJ. Intraoperative radiotherapy in the combination of adjuvant chemotherapy for the treatment of pT3N0M0 rectal cancer after radical surgery. *Am J Clin Oncol* 2014; **37**: 8-12 [PMID: 22892433 DOI: 10.1097/COC.0b013e31825eb75c]

36 **Zhang Q**, Tey J, Yang Z, Li P, Peng L, Fu S, Huang G, Xiong F, Lu JJ. Adjuvant chemoradiation plus intraoperative radiotherapy *vs* adjuvant chemoradiation alone in patients with locally advanced rectal cancer. *Am J Clin Oncol* 2015; **38**: 11-16 [PMID: 25616201 DOI: 10.1097/COC.0b013e318287bb8d]

37 **Knol J**, Keller DS. Total Mesorectal Excision Technique-Past, Present, and Future. *Clin Colon Rectal Surg* 2020; **33**: 134-143 [PMID: 32351336 DOI: 10.1055/s-0039-3402776]

38 **Kishan AU**, Voog JC, Wiseman J, Cook RR, Ancukiewicz M, Lee P, Ryan DP, Clark JW, Berger DL, Cusack JC, Wo JY, Hong TS. Standard fractionation external beam radiotherapy with and without intraoperative radiotherapy for locally recurrent rectal cancer: the role of local therapy in patients with a high competing risk of death from distant disease. *Br J Radiol* 2017; **90**: 20170134 [PMID: 28613934 DOI: 10.1259/bjr.20170134]

39 **Barry M**, Ho A, Morrow M. The evolving role of partial breast irradiation in early-stage breast cancer. *Ann Surg Oncol* 2013; **20**: 2534-2540 [PMID: 23463089 DOI: 10.1245/s10434-013-2923-8]

40 **Orecchia R**, Leonardo MC. Intraoperative radiation therapy: is it a standard now? *Breast* 2011; **20 Suppl 3**: S111-S115 [PMID: 22015276 DOI: 10.1016/S0960-9776(11)70307-1]

41 **Wiig JN**, Giercksky KE, Tveit KM. Intraoperative radiotherapy for locally advanced or locally recurrent rectal cancer: Does it work at all? *Acta Oncol* 2014; **53**: 865-876 [PMID: 24678823 DOI: 10.3109/0284186X.2014.895037]

42 **Erbe B**. [New developments in radiation therapy]. *Dtsch Med Wochenschr* 2014; **139**: 1090-1091 [PMID: 24945026 DOI: 10.1055/s-0034-1374686]

43 **van der Meij W**, Rombouts AJ, Rütten H, Bremers AJ, de Wilt JH. Treatment of Locally Recurrent Rectal Carcinoma in Previously (Chemo)Irradiated Patients: A Review. *Dis Colon Rectum* 2016; **59**: 148-156 [PMID: 26734974 DOI: 10.1097/DCR.0000000000000547]

44 **Vermeer TA**, Kusters M, Rutten HJ. T4 rectal cancer: do we always need an exenteration? *Recent Results Cancer Res* 2014; **203**: 69-94 [PMID: 25103001 DOI: 10.1007/978-3-319-08060-4\_8]

45 **Bikhchandani J**, Ong GK, Dozois EJ, Mathis KL. Outcomes of salvage surgery for cure in patients with locally recurrent disease after local excision of rectal cancer. *Dis Colon Rectum* 2015; **58**: 283-287 [PMID: 25664705 DOI: 10.1097/DCR.0000000000000283]

46 **Cantero-Muñoz P**, Urién MA, Ruano-Ravina A. Efficacy and safety of intraoperative radiotherapy in colorectal cancer: a systematic review. *Cancer Lett* 2011; **306**: 121-133 [PMID: 21414718 DOI: 10.1016/j.canlet.2011.02.020]

47 **Mirnezami R**, Chang GJ, Das P, Chandrakumaran K, Tekkis P, Darzi A, Mirnezami AH. Intraoperative radiotherapy in colorectal cancer: systematic review and meta-analysis of techniques, long-term outcomes, and complications. *Surg Oncol* 2013; **22**: 22-35 [PMID: 23270946 DOI: 10.1016/j.suronc.2012.11.001]

48 **Frasson AL**, Filho AB, Lichtenfels M, de Souza ABA, Vollbrecht B, Zerwes F. Effect of intraoperative radiotherapy for early breast cancer on 10-year recurrence rates and overall survival. *Breast J* 2020; **26**: 427-432 [PMID: 31538696 DOI: 10.1111/tbj.13502]

49 **Cifarelli CP**, Brehmer S, Vargo JA, Hack JD, Kahl KH, Sarria-Vargas G, Giordano FA. Intraoperative radiotherapy (IORT) for surgically resected brain metastases: outcome analysis of an international cooperative study. *J Neurooncol* 2019; **145**: 391-397 [PMID: 31654248 DOI: 10.1007/s11060-019-03309-6]

50 **Häfner MF**, Debus J. Radiotherapy for Colorectal Cancer: Current Standards and Future Perspectives. *Visc Med* 2016; **32**: 172-177 [PMID: 27493944 DOI: 10.1159/000446486]

**Footnotes**

**Conflict-of-interest statement:** No conflicts of interest.

**PRISMA 2009 Checklist statement:** The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Unsolicited manuscript

**Peer-review started:** November 10, 2020

**First decision:** November 30, 2020

**Article in press:**

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): A

Grade B (Very good): 0

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Maslennikov R **S-Editor:** Zhang L **L-Editor:** Filipodia **P-Editor:**

**Figure Legends**

****

**Figure 1 Study identification and selection flow chart.**

**Figure 2 Quality assessment of three randomized controlled trials.** A: Risk of bias summary; B: Risk of bias graph.

**Figure 3 Results of meta-analysis.** A: 5-yr overall survival; B: 5-yr disease-free survival.

****

**Figure 4 Results of meta-analysis: 5-year local control.**

**Figure 5 Results of meta-analysis: Abscess.**

**Figure 6 Results of meta-analysis: Fistulae.**

**Figure 7 Results of meta-analysis: Wound complications.**

**Figure 8 Results of meta-analysis: Fistulae anastomotic leakage.**

**Figure 9 Results of meta-analysis: Neurogenic bladder dysfunction.**

**Figure 10 Publication bias.** A: Results of Begg’s funnel plot; B: Egger’s publication bias plot for assessing publication bias of local control.

**Table 1 Baseline characteristics of the included studies**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Ref.** | **Year** | **Location** | **Time frame** | **Type** | **Patients, *n* IORT/ non-IORT** | **Age in yr, mean IORT non-IORT** | **Follow-up in mo, mean IORT non-IORT** | **Resection margin** | **Clinical stages, %** | **PR-RT, %** | **CT, %** | **PO-RT, %** | **IORT dose in Gy mean** | **NOS score** |
| Willett *et al*[23] | 1991 | United States | 1978-1988 | Observational studies | 20; 21/22; 2 | 64 v | 26 v | R0; R1/R2 | NA | 100 | NA | 0 | 15 | 7 |
| Suzuki *et al*[24] | 1995 | Germany | 1981-1988 | Observational studies | 42/64 | 64.3 v | 44 v | R1/R2 | NA | NA | NA | 98 | 20 | 8 |
| Huber *et al*[25] | 1996 | Germany | 1989-1993 | Observational studies | 36/18 | NA | 25.5 v | R0/R1/R2 | T3 (50); T4 (50) | 50 | 100 | 50 | 15 | 8 |
| Wiig *et al*[26] | 2002 | Norway | 1990-1999 | Observational studies | 59/48 | NA | NA | R0/R1/R2 | NA | 100 | NA | NA | 15-20 | 8 |
| Ratto *et al*[27] | 2003 | Italy | 1990-1997 | Observational studies | 19/24 | 62 | 74 v | NA | T3 (7); T4 (93) | NA | NA | NA | 10-15 | 7 |
| Sadahiro *et al*[28] | 2004 | Japan | 1991-2001 | Observational studies | 99/68 | 60 61 | 67 v | NA | T1/T2 (29); T3 (59); T4 (12) | 100 | 53 | 0 | 17.3 | 7 |
| Ferenschild *et al*[29] | 2006 | Netherlands | 1987-2001 | Observational studies | 30/93 | 66 v | 25 v | R0 | T2 (14); T3 (57); T4 (25) | 100 | NA | 0 | 10 | 9 |
| Masaki *et al*[30] | 2008 | Japan | 2000-2007 | RCT | 19/22 | NA | 34 v | NA | T1/T2 (11); T3 (89) | NA | 37 | NA | 18-20 f | RCT |
| Valentini *et al*[31] | 2009 | Italy | 1991-2006 | Observational studies | 11/35 | 62 v | 80 v | R0 | T4 (100) | NA | NA | NA | 10-15 f | 7 |
| Dubois *et al*[32] | 2011 | France | 1993-2001 | RCT | 72/68 | 62.5 64.5 | 60 v | NA | T3/T4 (100) | 100 | 25 | NA | 18 | RCT |
| Zhang *et al*[35] | 2014 | China | 1996-2007 | Observational studies | 45/46 | 61 61 | 72.9 v | NA | T3 (100) | NA | 100 | 51 | 20 | 8 |
| Alberda *et al*[33] | 2014 | Netherlands | 1996-2012 | Observational studies | 21; 22/31; 17 | 66 59/61 56 | 38 39/23 12 | R0/R1 | T3 (41); T4 (59) | NA | NA | NA | 10 | 8 |
| Klink *et al*[34] | 2014 | Germany | 2004-2012 | Observational studies | 52/111 | 62 63 | NA | R0 | T3/T4 (100) | NA | NA | NA | 10-20 f | 9 |
| Zhang *et al*[36] | 2015 | China | 1994-2007 | Observational studies | 71/77 | 58 63 | 72.3 v | R0/R1/R2 | T2 (6); T3 (52); T4 (42) | NA | 100 | 100 | 15 | 7 |
| Masaki *et al*[19] | 2020 | Japan | 2000-2017 | RCT | 38/38 | NA | 72 v | R0/R1 | T1/T2 (17); T3 (80); T4 (3) | NA | NA | NA | 18-20 f | RCT |

CT: Chemotherapy; f: Range reported with no mean/median; IORT: Intraoperative radiotherapy; NA: Not reported; non-IORT: Non-intraoperative radiotherapy; PO-RT: Post-operative radiotherapy; PR-RT: Pre-operative radiotherapy; RCT: Randomized controlled trial; v: Reported for IORT and non-IORT combined.

**Table 2 Outcome indicators of the included studies**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Ref.** | **Surgery, %** | **Resection margin** | **5-yr OS, % IORT non-IORT** | **5-yr DFS, % IORT non-IORT** | **5-yr LC, % IORT non-IORT** | **Complications, % IORT non-IORT** |
| Willett *et al*[23] | NA | R0; R1/R2 | NA | 53 60; 32 NA | 88 71; 60 0 | Abscess (5); Fistulae (7) Wound (5); Anastomotic leakage (2) Ureteric obstruction (2) Sacral necrosis (2) | NA |
| Suzuki *et al*[24] | LAR (57); APR (35); Hartmann (6) | R1/R2 | 19 7.3 | 30 5.9 | 60 7 | Pelvic abscess (12) Fistula (2) Perineal wound (7); Small bowel obstruction (14) Ureteral obstruction (7) | Pelvic abscess (11) Fistula (6) Perineal wound (2); Small bowel obstruction (5) Ureteral obstruction (2) |
| Huber *et al*[25] | LAR (84); APR (16) | R0/R1/R2 | 40 20 | 28 NA | 80 24 | Wound (45) Sacral wound dehiscence (21); Neurogenic bladder dysfunction (8) | Wound (58) Sacral wound dehiscence (26); Neurogenic bladder dysfunction (11) |
| Wiig *et al*[26] | LAR (31); APR (10); Hartmann (19) | R0/R1/R2 | 30 35 | NA | 44 28 | Abscess (24) wound (3) Anastomotic leakage (3); Late perineal healing (10) | Abscess (29) wound (13) Anastomotic leakage (13); Late perineal healing (2) |
| Ratto *et al*[27] | LAR (33); APR (56) | NA | NA | 47 39 | 91 57 | NA |
| Sadahiro *et al*[28] | LAR (54); APR (46) | NA | 79 58 | 71 54 | 98 84 | Anastomotic leakage (6) Wound (23) Bleeding (3) Neurogenic bladder dysfunction (2) | Anastomotic leakage (3) Wound (12) Bleeding (1) Neurogenic bladder dysfunction (4) |
| Ferenschild *et al*[29] | NA | R0 | 56 66 | NA | 71 72 | NA |
| Masaki *et al*[30] | TME (100) | NA | 64 NA | 60 NA | 95 95 | Anastomotic breakdown (25) Intrapelvic abscess (14) | Anastomotic breakdown (14) Intrapelvic abscess (21) |
| Valentini *et al*[31] | APR (56) | R0 | 19.4 16.3 | 41.1 16.8 | 79.5 23.7 | NA |
| Dubois *et al*[32] | APR (20) | NA | 77 75 | 62 66 | 92 93 | Anastomotic leakage (8.5) Re-operation (11.3) Infectious complications (9.9) Medical complications (7.0) Sacral necrosis (1.5) | Anastomotic leakage (4.4) Re-operation (8.8) Infectious complications (11.8) Medical complications (2.9) |
| Zhang *et al*[35] | TME (80) | NA | 84 86 | 71 73 | 84 86 | Grade 3 diarrhea (3) numbness and motor weakness (4.4) | Leukopenia (10.9) Grade 3 diarrhea (14) incomplete intestinal obstruction (6.5) acute mucositis of the anal verge (23.9) |
| Alberda *et al*[33] | TME (100) | R0; R1 | 63 81; 41 13 | NA | 70 79; 84 41 | Abdominal/perineal wound infections (31) abscess (6) Anastomotic leakage (2) Urinary tract infection (8) Cardiac (6) | Abdominal/perineal wound infection (23) abscess (13) Anastomotic leakage (3) Urinary tract infection (8) Cardiac (3) |
| Klink *et al*[32] | NA | R0 | NA | NA | NA | Postoperative bleeding (0) Anastomotic leakage (11) Surgical site infection (15) Abscess (10) Fistula (2) Stenosis (4) Bladder dysfunction (8) Urethral leakage (0) Sexual dysfunction (2) | Postoperative bleeding (4) Anastomotic leakage (14) Surgical site infection (9) Abscess (5) Fistula (0) Stenosis (1) Bladder dysfunction (10) Urethral leakage (1) Sexual dysfunction (3) |
| Zhang *et al*[36] | TME (100) | R0/R1/R2 | 74.6 66.2 | 69 58.5 | 89.7 79 | Incomplete intestinal obstruction (4) Hydronephrosis (7) | Incomplete intestinal obstruction (2.6) Hydronephrosis (10) |
| Masaki *et al[*19] | TME (100) | R0/R1 | 71.5 81.8 | NA | 87.6 91.7 | Anastomotic leakage (29) abscess (18) Small bowel obstruction (13) | Anastomotic leakage (13) abscess (11) Small bowel obstruction (18) |

APR: Abdominoperineal resection; DFS: Disease-free survival; LAR: Low anterior resection; LC: Local control; NA: Not reported; non-IORT: Non-Intraoperative radiotherapy; OS: Overall survival; TME: Total mesorectal excision.

**Table 3 Results of meta-analysis and subgroup analysis by intraoperative radiotherapy compared with non-intraoperative radiotherapy for rectal cancer**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Outcome indicators** | **Study type** | **NO of study** | **Patients, *n* IORT non-IORT** | **HR/OR/WMD (95% CI)** | ***P* value** | **Heterogeneity, *c*2/ *I*2/ *p* value** |
| 5-yr overall survival | RCT | 3 | 129 95 | 0.68 (0.29-1.63) | 0.390 | 2.92/31.4%/0.233 |
| Observational studies | 6 | 321 292 | 0.81 (0.66-1.11) | 0.189 | 2.21/0.0%/0.819 |
| Totality | 9 | 450 387 | 0.80 (0.60-1.06) | 0.126 | 5.16/0.0%/0.740 |
| 5-yr disease free survival | RCT | 2 | 91 57 | 1.61 (0.74-3.53) | 0.231 | 0.60/0.0%/0.440 |
| Observational studies | 4 | 235 212 | 0.89 (0.68-1.16) | 0.374 | 1.72/0.0%/0.633 |
| Totality | 6 | 326 269 | 0.94 (0.73-1.22) | 0.650 | 4.33/0.0%/0.503 |
| 5-yr local control | RCT | 3 | 129 95 | 1.37 (0.35-5.35) | 0.655 | 1.33/24.8%/0.249 |
| Observational studies | 11 | 487 511 | 3.38 (1.73-6.57) | 0.000 | 41.31/73.4%/0.000 |
| Totality | 14 | 616 606 | 3.07 (1.66-5.66) | 0.000 | 43.42/70.9%/0.000 |
| Abscess | RCT | 2 | 57 60 | 1.83 (0.65-5.11) | 0.252 | 0.01/0.0%/0.905 |
| Observational studies | 4 | 205 262 | 0.94 (0.53-1.66) | 0.833 | 1.99/0.0%/0.575 |
| Totality | 6 | 262 322 | 1.10 (0.67-1.80) | 0.713 | 3.22/0.0%/0.665 |
| Fistulae | RCT | 1 | 72 68 | 0.75 (0.30-1.88) | 0.542 | 0.00/NA/NA |
| Observational studies | 2 | 94 175 | 1.22 (0.08-18.77) | 0.888 | 2.02/50.4%/0.156 |
| Totality | 3 | 166 243 | 0.79 (0.33-1.89) | 0.600 | 2.07/3.2%/0.356 |
| Wound complications | RCT | 1 | 72 68 | 0.75 (0.30-1.88) | 0.542 | 0.00/NA/NA |
| Observational studies | 7 | 385 393 | 1.06 (0.47-2.37) | 0.893 | 16.09/62.7%/0.013 |
| Totality | 8 | 457 461 | 1.21 (0.62-2.36) | 0.575 | 17.01/58.8%/0.017 |
| Anastomotic leakage | RCT | 3 | 129 95 | 2.18 (0.89-5.33) | 0.087 | 0.11/0.0%/0.946 |
| Observational studies | 4 | 262 266 | 0.66 (0.31-1.41) | 0.283 | 2.46/0.0%/0.482 |
| Totality | 7 | 391 361 | 1.09 (0.59-2.02) | 0.775 | 6.57/8.7%/0.363 |
| Neurogenic bladder dysfunction | Observational studies | 3 | 187 197 | 0.69 (0.31-1.55) | 0.369 | 0.27/0.0%/0.874 |

HR: Hazard ratio; IORT: Intraoperative radiotherapy; NA: Not reported; non-IORT: Non-Intraoperative radiotherapy; OR: Odds ratio; RCT: Randomized controlled trial; WMD: Weighted mean difference.